Known as the brand name anti-epileptic drug Dilantin, Phenytoin has recently piqued the interests of Multiple Sclerosis research and development teams. Study results shared from the National Hospital for Neurology and Neurosurgery in London have been hopeful for patients with MS who were treated with Phenytoin, in response to their cases of acute optic neuritis.[…]
Can Phenytoin Aid the Eyesight of Patients with MS?
Anticonvulsant, Drug Research & Development API, OTC and Compounding Product Tags: MSmultiple sclerosis Jun 04, 2015
Alemtuzumab is a Formidable Therapy for Cancer and Multiple Sclerosis
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: MSmultiple sclerosisUnited States Mar 18, 2015
Known as the brand name Campath, which is marketed by Genzyme, Alemtuzumab is a proven therapy for leukemias, lymphomas and recently, multiple sclerosis. As a monoclonal antibody Alemtuzumab effectively binds to the CD52 protein which occurs on cancerous B and T cell lymphocytes. After attaching to the protein on the cells Alemtuzumab elicits other immune[…]
FDA Approves Efficacious and Long-Acting MS Drug Alemtuzumab
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014, Monoclonal Antibodies / mAb Tags: AlemtuzumabLemtradaMS Nov 19, 2014
Alemtuzumab, also known as the brand name MS drug Lemtrada, has recently gained a long awaited FDA approval. Genzyme spent over a decade developing this long-acting agent designed to effectively treat patients with relapsing Multiple Sclerosis. The unique method of dispensing Alemtuzumab is a significant plus for patients who do not tolerate current medication regimens[…]
Daclizumab Passes Phase III Hurdles
Immunosuppressant, Monoclonal Antibodies / mAb Tags: MSmultiple sclerosis Jul 03, 2014
Exciting news has been shared by Abbvie and Biogen regarding Daclizumab and it’s now brighter future. The once a month treatment for MS has now cleared all major Phase III hurdles, making a marketing pitch to FDA regulators foreseeable in the near future. As an injectable medication designed to combat the debilitating symptoms of Multiple[…]
FDA Approves Twice a Day Dose of Dimethyl Fumarate for MS
Immunosuppressant Tags: glatiramer acetateMSmultiple sclerosis Apr 15, 2013
The recent approval of dimethyl fumarate CAS# 624-49-7, on March 27th, 2013, was an encouraging sign for the 2.5 million patients worldwide who are suffering with Multiple Sclerosis. The FDA approved Tecfidera, the brand name for dimethyl fumarate, which is developed by Biogen. As easy to dispense oral capsules, this new treatment for MS is[…]
Shocking Diagnosis of Reality Star Creates a Whirlwind of Attention for Glatiramer Acetate
Drug Research & Development API, Immunological Agent, Patent Expiration 2014 Tags: dexamethasoneglatiramer acetateMSmultiple sclerosis Jun 22, 2012
Glatiramer, CAS# 28704-27-0, and Glatiramer Acetate, CAS# 147245-92-9, are also known as Copaxone. In the spotlight recently, Copaxone’s patent is due to expire on May 24, 2014. The flurry of interest regarding Copaxone follows the devastating diagnosis of Multiple Sclerosis for beloved reality star Jack Osbourne. In mid June of 2012 reports surfaced about Jack’s[…]
